CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn is actually  a   biotech that has proved helpful hard but unsuccessfully to develop an one-time therapy, variously named Pro 140, leronlimab, along with Vyrologix.

In development of this therapy, CytoDyn has cast its net wide and far both geographically and in phrases of prospective indications.

CytoDyn’s inventories of leronlimab are building up, whether they will ever be being used is an open question.

While CYDY  is actually dawdling, market opportunities for leronlimab as being a combination therapy in the curing of multi-drug-resistant HIV are actually closing.

I am writing my fifteenth CytoDyn (OTCQB:CYDY) report on FintechZoom to celebrate the sale of the past several shares of mine. The first CytoDyn post of mine, “CytoDyn: What In order to Do When It is Too Good To Be True?”, set away the following prediction:

Rather I expect it to turn into a serial disappointer. CEO Pourhassan offered such a highly promotional image in the Uptick Newswire interview that I came away with a poor opinion of the business.

Irony of irony, the poor impression of mine of the business enterprise has grown steadily, though the disappointment has not been financial. 2 many years ago CytoDyn was trading <$1.00. On 2/19/20 as I write, it trades during $5.26; the closing transaction of mine was on 2/11/21 > $6.00.

What manner of stock  is it that delivers a > six bagger at the moment still disappoints? Therein lies the story; allow me to explain.

CytoDyn acquired its much storied treatment (which I shall refer to as leronlimab) returned in 2012, announced as follows:

CytoDyn Inc…. has finished the acquisition of Pro 140, an experimental humanized monoclonal antibody (MAB) looking for the CCR5 receptor for the therapy as well as prevention of HIV, coming from Progenics Pharmaceuticals, Inc. of Tarrytown, NY. Pro 140 is a late Stage II clinical growth mAb with demonstrated anti-viral activity in HIV infected subjects. Today’s transaction of $3.5 million transfers ownership of the expertise and connected intellectual property from Progenics to CytoDyn, as well as roughly 25 million mg of majority drug substance…. milestone payments after commencement of a level III clinical trial ($1.5 million) and also the first brand new drug program approval ($5 million), and even royalty payments of five percent of net sales upon commercialization.

Since that moment, CytoDyn’s guiding nous, Nader Pourhassan [NP] has made this inauspicious acquisition into a springboard for CytoDyn to purchase a market cap > $3.5 billion. It has done so in exclusive reliance on leronlimab.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

Instead of having a pipeline with numerous indications and many therapies, it has this single remedy in addition to a “broad pipeline of indications” as it places it. I call some pipelines, “pipedots.” In CytoDyn’s case it touts its leronlimab as a potentially beneficial therapy in dozens of indications.

Its opening banner on its website (below) shows an active company with diverse interests albeit centered on leronlimab, multiple illness types, multiple publications in addition to multiple delivering presentations.

Could all this be smoke cigarettes and mirrors? That’s a question I’ve been asking myself from the very start of my interest in this business. Judging by way of the multiples of a huge number of several comments on listings accessible via Seeking Alpha’s CytoDyn Summary webpage, I am a lot from alone in this question.

CytoDyn is a classic battleground, or perhaps some could say cult inventory. Its adherents are fiercely protective of the prospects of its, quick to label any negative opinions as scurrilous short mongering.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News